Cyclophosphamide for GVHD Continues to Extend Stem-Cell Transplant Eligibility

(MedPage Today) — Patients who underwent stem cell transplants (SCTs) involving mismatched unrelated donors (MMUDs) had a 1-year overall survival (OS) of about 80% with post-transplant cyclophosphamide (PTCy)-based prophylaxis for graft-versus…

Source link : https://www.medpagetoday.com/hematologyoncology/hematology/116263

Author :

Publish date : 2025-06-26 16:04:00

Copyright for syndicated content belongs to the linked Source.

M	T	W	T	F	S	S
				1	2	3
4	5	6	7	8	9	10
11	12	13	14	15	16	17
18	19	20	21	22	23	24
25	26	27	28	29	30	31

Cyclophosphamide for GVHD Continues to Extend Stem-Cell Transplant Eligibility

Make America Fit Again

$2M Award in Decapitated Baby Case; Doc Accused of Removing Fentanyl From IV Line

Related Posts

Low FT3 Levels Predict Risk for Nerve Damage in Diabetes

Low Disease Activity Maintained Long Term With TNF Tapering

New Anti-VEGF Agents Extend Dosing Intervals in Wet AMD

Anemia Tied to Cognitive Decline in Dialysis Patients

CPAP May Prevent BP Rise in Normotensive Sleep Apnea

Blood Cell Patterns Predict Poor Venetoclax Response

Low FT3 Levels Predict Risk for Nerve Damage in Diabetes

Low Disease Activity Maintained Long Term With TNF Tapering

New Anti-VEGF Agents Extend Dosing Intervals in Wet AMD

Anemia Tied to Cognitive Decline in Dialysis Patients

CPAP May Prevent BP Rise in Normotensive Sleep Apnea

Blood Cell Patterns Predict Poor Venetoclax Response

Psoriasiform Dermatitis Risk in Children on TNFi Reviewed

The flaws in medical evidence on all sides of the Lucy Letby case

Categories

Archives